Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

InnoCare to Start BCL2 Inhibitor Trial in US for Hematological Cancers

publication date: Jan 16, 2024

Beijing InnoCare Pharma was approved to start US clinical trials for its B-cell lymphoma-2 (BCL2) inhibitor, ICP-248, the company’s fifth innovative candidate to start US trials. ICP-248 is an orally bioavailable BCL2-selective inhibitor that is expected to treat hematologic malignancies as a monotherapy or in combination with other therapies. The abnormal expression of BCL2, a regulatory protein of the apoptosis pathway, is related to the development of several hematologic malignancies. InnoCare has already started a Phase I dose escalation trial of ICP-248 is China, where preliminary results showed good efficacy and safety profiles. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital